Brief: Y-Mabs Therapeutics Announces U.S. FDA Clearance Of Investigational New Drug Application For Cd38-Sada
17/10/2023 21:19
Oct 17 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O :
* Y-MABS THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR CD38-SADA
* Y-MABS THERAPEUTICS INC: LOOK FORWARD TO INITIATING
CD38-SADA
PHASE 1 TRIAL AND EXPECT TO DOSE FIRST PATIENT IN 2024
Source text for Eikon: ID:nGNX2RVqp2
Further company coverage: YMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Y-mAbs Therapeutics
See all newsY-mAbs Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Y-mAbs Therapeutics' Q2 revenue falls 14%
Brief: Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics
Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary